Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Doximity, Inc. (DOCS) SEC filings page provides access to the company’s official regulatory disclosures as a New York Stock Exchange–listed issuer. Doximity files annual, quarterly, and current reports that describe its financial condition, results of operations, governance matters, and material events affecting the business.
In its filings and related press releases, Doximity presents condensed consolidated balance sheets, statements of operations, and statements of cash flows, along with discussions of non-GAAP financial measures. The company explains how it calculates metrics such as non-GAAP gross profit, non-GAAP net income, adjusted EBITDA, and free cash flow, and provides reconciliations to GAAP results. These documents allow readers to see how Doximity evaluates its performance beyond standard accounting measures.
Current reports on Form 8-K for DOCS include items such as quarterly earnings announcements, changes in executive roles, annual meeting voting results, and legal developments. For example, Doximity has filed 8-Ks to furnish earnings press releases, to report the outcomes of its annual meeting of stockholders, to disclose changes in its general counsel and related roles, and to describe a securities litigation settlement agreement that remains subject to court approval and other customary conditions.
Through its proxy materials and related filings, Doximity also reports on corporate governance topics, including the election of directors, ratification of its independent registered public accounting firm, and advisory votes on executive compensation. Voting results, including the participation of Class A and Class B common stock, are detailed in these documents.
On this page, AI-powered tools can summarize lengthy DOCS filings, highlight key sections on revenue trends, profitability, cash flows, and risk disclosures, and surface notable items such as settlement agreements or executive transitions. Users can quickly review quarterly reports, annual reports, and Form 4 and other transaction-related filings, while relying on real-time updates from the SEC’s EDGAR system to follow new disclosures from Doximity, Inc.
Doximity, Inc. (DOCS) director Phoebe L. Yang received a grant of 3,221 restricted stock units (RSUs) on 08/28/2025 under the company’s non-employee director compensation policy. Each RSU converts to one share of Class A common stock upon vesting. The RSUs vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, subject to the reporting person’s continued service as a director. After the grant, Ms. Yang beneficially owns 17,950 shares of Class A common stock. The grant was reported via Form 4 and executed on 08/28/2025.
Kira Scherer Wampler, a director of Doximity, Inc. (DOCS), was granted 3,221 restricted stock units (RSUs) on 08/28/2025 under the company's non-employee director compensation policy. Each RSU represents a contingent right to one share of the issuer's Class A Common Stock and the award vests in full on the earlier of the first anniversary of the grant date or the issuer's next annual meeting of stockholders, subject to continued service as a director.
Following the reported grant, the reporting person beneficially owns 19,839 shares of Class A Common Stock. The Form 4 was submitted with a signature by an attorney-in-fact on 09/02/2025.
Timothy S. Cabral, identified as a director of Doximity, Inc. (DOCS), was granted 3,221 restricted stock units (RSUs) on 08/28/2025 under the company’s non-employee director compensation policy. Each RSU is a contingent right to one share of Class A Common Stock and was granted at no cash price ($0). The RSUs vest in full on the earlier of the first anniversary of the grant date or the issuer’s next annual meeting of stockholders, subject to continued service as a director. After the grant, the reporting person beneficially owned 9,581 shares of Class A Common Stock.
Benjamin Regina M., a director of Doximity, Inc. (DOCS), received a grant of 3,221 restricted stock units (RSUs) on 08/28/2025 under the issuer's non-employee director compensation policy. Each RSU represents a contingent right to one share of Class A common stock and the grant was reported with a transaction price of $0. The RSUs vest in full on the earlier of the first anniversary of the grant date or the issuer's next annual meeting of stockholders, subject to the reporting person's continued service as a director through the applicable vesting date. After the grant, the reporting person beneficially owned 19,839 shares of Class A common stock on a direct basis. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/02/2025.
Kevin Spain, a director of Doximity, Inc. (DOCS), received 3,221 restricted stock units (RSUs) on 08/28/2025 as compensation under the company’s non-employee director policy. Each RSU converts to one share of Class A common stock and vests in full on the earlier of the first anniversary of the grant or the next annual meeting, subject to continued service. After the grant Mr. Spain directly beneficially owned 9,581 Class A shares, which includes 3,221 RSUs and 6,360 previously vested shares. He also has indirect holdings of 244,607 shares in The Kevin Spain Family Trust and 387,500 shares held by Emergence Capital Opportunity I, L.P., of which he is affiliated; he disclaims beneficial ownership of those indirect holdings except for any pecuniary interest.
Doximity, Inc. (DOCS) filing a Form 144 reports a proposed sale of 6,360 restricted common shares with an aggregate market value of $421,655.28, scheduled approximately for 09/02/2025 on the NYSE. The filing shows the shares were acquired as restricted stock on 08/28/2025 and lists total outstanding common shares of 187,299,459. The filer also disclosed sales during the past three months by Timothy Cabral: 20,000 shares sold on 08/15/2025 for $1,275,566.00 and 10,000 shares sold on 06/25/2025 for $600,000.00. Other customary Form 144 statements and signature cautions are included.
Doximity, Inc. (DOCS) Form 144 notice: An insider proposes to sell 2,000 common shares through Morgan Stanley Smith Barney on 09/02/2025 on the NYSE, with an aggregate market value of $133,140.00. The securities were acquired the same day via a stock option exercise and paid in cash. The filer previously sold 2,000 shares on 08/01/2025 for $114,180.00 and 2,000 shares on 07/01/2025 for $121,920.00. The filing includes the required representation that the seller does not possess undisclosed material adverse information.
Doximity, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on August 28, 2025. Stockholders representing 97.51% of the voting power were present, providing a strong quorum for conducting company business.
Two Class I directors, Jeff Tangney and Kira Wampler, were elected to serve until the 2028 annual meeting. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. In addition, stockholders approved, on a non-binding advisory basis, the compensation of Doximity’s named executive officers for the fiscal year ended March 31, 2025.
Doximity CFO Anna Bryson reported transactions on 08/26/2025. The filing shows the Reporting Person acquired 40,000 shares of Class A common stock through conversion/exercise and simultaneously sold 40,000 shares pursuant to a Rule 10b5-1 trading plan adopted on 05/27/2025. The sales were executed at a weighted-average price of $66.7561 per share, with sale prices ranging from $66.2250 to $67.2200. Following these transactions the Reporting Person beneficially owns 346,925 shares (direct). The filing also discloses outstanding stock option activity related to 40,000 options with an $8.26 exercise price.
Insider transactions by Doximity director Timothy S. Cabral on 08/15/2025: Mr. Cabral converted 20,000 shares of Class B common stock into Class A shares and exercised 20,000 stock options with a $2.21 exercise price, resulting in 20,000 newly acquired Class A shares. He sold 16,200 Class A shares at a weighted-average price of approximately $63.682 and an additional 3,800 Class A shares at a weighted-average price of approximately $64.1889, under a Rule 10b5-1 trading plan adopted February 13, 2025. After these transactions he directly held 10,160 and 6,360 Class A shares as reported across sales; total Class B and exercised option conversions are noted as convertible to Class A.